Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: A case report

被引：6

作者：

Agosti S. ^{[1
]}

Casalino L. ^{[2
]}

Rocci E. ^{[3
]}

Zaccone G. ^{[1
]}

Rota E. ^{[3
]}

机构：

[1] Cardiology Department, San Giacomo Hospital, Novi Ligure, Alessandria

[2] Cardiology Unit, ASL 3, Genoa

[3] Neurology Unit, San Giacomo Hospital, Novi Ligure, Alessandria

来源：

Journal of Medical Case Reports | / 11卷 / 1期

关键词：

Dabigatran; Idarucizumab; Ischemic stroke; Non-Vitamin K antagonist oral anticoagulants; Thrombolysis;

D O I：

10.1186/s13256-017-1404-2

中图分类号：

学科分类号：

摘要：

Background: Non-vitamin K antagonist oral anticoagulants, including dabigatran, are currently widely used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Recently, idarucizumab, a monoclonal antibody fragment for immediate reversal of dabigatran-induced anticoagulation, has been introduced into the market to be used in life-threatening bleeding or urgent surgery, allowing for rapid normalization of clotting parameters. The use of idarucizumab is not yet well established in patients presenting with acute ischemic stroke on dabigatran who are candidates for thrombolytic therapy. Case presentation: We report the case of a 71-year-old hypertensive Caucasian woman with non-valvular atrial fibrillation treated with dabigatran 150 mg twice daily, who presented with acute ischemic stroke causing right-sided hemiparesis and aphasia. Two hours after presentation to the emergency department, a decision was made to administer idarucizumab for achieving complete reversal of any potential anticoagulant effect of dabigatran and, in the absence of any contraindications, our patient underwent successful thrombolysis. At discharge, our patient was able to walk unassisted and had only residual aphasia. Twenty days later, she had completely recovered motor function of her right side, with further progressive improvement of aphasia. Repeat cranial computed tomography confirmed the absence of hemorrhage, and anticoagulant therapy with dabigatran 150 mg twice daily was resumed. Conclusions: Our case report adds to the evidence that idarucizumab administration is safe in the setting of patients with atrial fibrillation treated with dabigatran who develop acute ischemic stroke requiring thrombolysis. © 2017 The Author(s).

引用

共 17 条

[1]

Garber J.L., Willenborg K.L., Rose A.E., Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection, J Thromb Thrombolysis, 40, pp. 248-254, (2015)

[2]

Kumar S., Danik S.B., Altman R.K., Barrett C.D., Lip G.Y., Chatterjee S., Et al., Non-Vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: A meta-analysis of randomized controlled trials, Cardiol Rev, 24, pp. 218-223, (2016)

[3]

Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, pp. 1139-1151, (2009)

[4]

Pollack C.V., Reilly P.A., Eikelboom J., Glund S., Verhamme P., Bernstein R.A., Et al., Idarucizumab for dabigatran reversal, N Engl J Med, 373, pp. 511-520, (2015)

[5]

Ansell J.E., Reversing the effect of oral anticoagulant drugs: Established and newer options, Am J Cardiovasc Drugs, 16, pp. 163-170, (2016)

[6]

Turine G., Peeters A., Hermans C., Eeckhoudt S., Duprez T., Intravenous thrombolysis after reversal of dabigatran by idarucizumab: A moment to be a pioneer, Acta Neurol Belg, (2017)

[7]

Schafer N., Muller A., Wullner U., Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab - A case report, J Stroke Cerebrovasc Dis, 25, pp. e126-e127, (2016)

[8]

Kafke W., Kraft P., Intravenous thrombolysis after reversal of dabigatran by idarucizumab: A case report, Case Rep Neurol, 8, pp. 140-144, (2016)

[9]

Gawehn A., Ayari Y., Heuschkel C., Kaste M., Kermer P., Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: A case report, J Med Case Rep, 10, (2016)

[10]

Mutzenbach J.S., Pikija S., Otto F., Halwachs U., Weymayr F., Sellner J., Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - A case report, Ann Clin Transl Neurol, 3, pp. 889-892, (2016)

← 1 2 →